1. Introduction {#s0005}
===============

Mc Cune Albright Syndrome (MAS) is a rare disorder defined by the classical triad of polyostotic fibrous dysplasia (FD), "café-au-lait" skin hyperpigmentation and hyperfunctioning endocrinopathies, such as precocious puberty.

MAS is caused by an activating post zygotic somatic mutation of GNAS gene, coding for the alpha-subunit of the stimulatory G protein (Gsalpha), involved in the cAMP cascade, referred to as a gsp mutation ([@bb0200]). This mutation leads to elevated levels of intracellular cAMP and activation of downstream-dependent pathways. In endocrine tissues, this mutation results in overproduction of hormones and endocrine cell hyperfunction and proliferation.

MAS is associated with hyperfunction of multiple endocrine tissues, including excess of growth hormone (GH) secretion ([@bb0055]), hyperthyroidism ([@bb0060]; [@bb0050]; [@bb0190]; [@bb0175]; [@bb0130]) or Cushing\'s syndrome ([@bb0020]).

Whereas the association of hyperthyroidism or thyroid adenomas ([@bb0060]; [@bb0050]; [@bb0190]; [@bb0175]; [@bb0130]) is well known in MAS, the relationship with thyroid carcinoma has rarely been observed ([@bb0035]; [@bb0040]; [@bb0210]).

We report a new case of GNAS mutated thyroid carcinoma in a patient with MAS.

2. Case report {#s0010}
==============

A 18 years old woman with known MAS presented with subclinical hyperthyroidism during her annual follow-up work up.

Her MAS was diagnosed at age 6 because of abnormal bleeding in relation with precocious puberty. She also had skin "café au lait" spots, polyostotic FD, renal phosphate wasting and growth hormone excess.

At age 18, her systematic follow up measurement showed subclinical hyperthyroidism with suppressed serum TSH, less than 0.01 mUI/ml (normal 0.4--3.1), elevated T3 level at 5.2 pmol/L (normal 2.9--4.9) and a slight decrease of T4 concentration (11.2 pmol/L -- normal 12--22) suggestive of autonomous functioning thyroid nodule producing T3. She had no symptoms of thyrotoxicosis. There was no history of radiation exposure to the neck.

Her mother had an history of toxic multinodular goiter.

Neck ultrasonography showed hypertrophy of the right lobe and 3 nodules including one hypervascularized nodule of 25 × 20 × 30 mm in the right lobe, classified TIRADS 3.

A technetium-99 m pertechnetate thyroid scintigraphy scan showed a strong hyperfixation at the location of the nodule ([Fig. 1](#f0005){ref-type="fig"}). The patient underwent a right hemithyroidectomy and the pathology revealed a follicular thyroid neoplasm. Genetics analysis using next generation sequencing showed the presence of the R201C GNAS mutation in neoplastic thyroid cells. No other mutation (including BRAF and N RAS) was detected. The surgery will be extended to a total thyroidectomy. An initial surgical treatment was preferred over iodine treatment because of the increased risk of sarcomatous transformation of skull FD lesions in context of MAS and GH excess that has been observed in case of radiotherapy ([@bb0135]; [@bb0090]; [@bb0170]).Fig. 1Thyroid imaging.(A) Thyroid ultrasonography showed the largest thyroid nodule in the right lobe (25 ∗ 20 ∗ 35 mm) classified TIRADS 3 and the normal left lobe (arrow).(B) This nodule showed as excess trapping of isotope in technetium-99 m pertechnetate scintigraphy (dashed arrow) against a low background of the thyroid (arrow).Fig. 1

3. Discussion {#s0015}
=============

Somatic mutations of GNAS have been implicated in various sporadic endocrine and non - endocrine tumors, such as pituitary adenomas ([@bb0110]; [@bb0215]; [@bb0160]; [@bb0195]; [@bb0070]), thyroid adenomas and carcinomas ([@bb0035]; [@bb0215]; [@bb0120]; [@bb0145]; [@bb0150]; [@bb0115]), Leydig cell tumors ([@bb0065]), ovarian tumors ([@bb0010]; [@bb0030]), breast cancer ([@bb0040]; [@bb0180]; [@bb0185]; [@bb0125]), pancreatic and hepatobiliary tumors ([@bb0155]; [@bb0080]; [@bb0085]) leading to the term "gsp oncogene".

Regarding thyroid tumors, somatic GNAS mutations have been reported in thyroid carcinomas, out of the context of MAS/FD. Indeed, [@bb0145], have analyzed the presence of activating Gs mutations in 38 differentiated human thyroid benign tumors by polymerase chain reaction amplification and oligonucleotide hybridization. Activating Gs mutations were identified in 5 of 13 (38%) autonomously functioning adenomas, but in none of other thyroid tumors (nonfunctioning adenomas, papillary carcinomas or follicular carcinomas). In this study, authors had concluded that the *gsp* oncogene was involved in the pathogenesis of autonomously functioning tumors but did not support a role in other thyroid tumors.

[@bb0215], have screened Gs alpha mutations (at codons 201 and 227) by PCR and the mutation was present in 4 of 66 thyroid tumors (30 papillary carcinomas) and these 4 thyroid tumors were papillary carcinomas. They concluded that Gs alpha mutations at these two loci may play a role in the pathogenesis of a small population of papillary thyroid carcinomas.

[@bb0115], reported the observation of a follicular thyroid carcinoma, with both NRAS pQ61K and GNAS pR201H mutation in a 79 year old-man with history of Grave\'s disease. NRAS and GNAS mutations were only found in neoplastic thyroid tissue.

The presence of thyroid abnormalities in MAS, such as hyperthyroidism, goiter and thyroid adenomas is well known ([@bb0040]): hyperthyroidism is the second most common endocrinopathy in MAS. At the National Institute of Health (NIH), approximately 2/3 of the patients with MAS had involvement of thyroid, when assessed by thyroid ultrasound (US) ([@bb0040]).

Activating GNAS mutation in thyroid tissue results in activation of the TSH/G protein/cAMP pathway which is leading to hyperplasia and thyroid hormone production and increased conversion from T4 to T3 ([@bb0045]; [@bb0025]).

However, association of MAS with thyroid malignancies is rare. So far, two cases of thyroid cancer have been described in MAS patients (1.3%) from the NIH cohort ([@bb0040]): one case of papillary thyroid cancer in a 14 year old girl and another case of clear cells thyroid carcinoma in a 42 year old woman. In both instances, the Gs mutation was found in the neoplastic tissue. Interestingly, the Gs mutation was not found in adjacent normal tissue. This data supports the oncogenic role of GNAS mutation on endocrine tissue ([@bb0035]).

Another case of lipid-rich follicular carcinoma of the thyroid was reported by Yang GC et al., in a 41 year old woman with MAS ([@bb0210]).

Incidence of thyroid carcinomas is low, and MAS is also a rare disease. Therefore, in this observation, it is unlikely that the presence of GNAS mutated thyroid carcinomas and MAS was incidental.

Malignancies can involve other endocrine tissues of patients with MAS.

Indeed, women with polyostotic fibrous dysplasia and/or MAS have an increased risk of breast cancer ([@bb0040]; [@bb0180]; [@bb0185]; [@bb0125]). In a cohort of women with FD from Netherlands and United States ([@bb0125]), breast cancer risk was 3.9 fold increased (95% CI 1.2--8.2) compared with the general population. Risk of breast cancer was increased at a younger age, especially in polyostotic FD and thoracic FD lesions. GNAS mutations were identified in pathological specimens of breast tumors in 4 of 9 patients with fibrous dysplasia (44%) compared with less than 1% reported incidence of GNAS positive breast cancer in the general population. Thus, authors recommended screening for breast cancer in women with FD, at a younger age than women in the general population.

In the same way, MAS is associated with GH excess and pituitary adenomas ([@bb0005]) and GNAS mutations have been identified in human pituitary tumors in non-MAS patients ([@bb0110]; [@bb0215]; [@bb0120]). Thus, a pituitary MRI is indicated in case of abnormal hormonal blood tests (IGF1, GH, prolactin) ([@bb0095]).

Rare cases of testicular and ovarian malignancies were described in MAS: one patient with testicular cancer (both embryonal carcinoma and a seminoma) was reported by the NIH ([@bb0015]). One case of ovarian virilizing sclerosing-stromal tumor and one case of ovarian epithelial tumor harboring a GNAS mutation were reported ([@bb0010]; [@bb0030]).

The putative pathogenic effect of GNAS in these tumors is supported by the identification of the R201C mutation in ovarian and testicular Leydig cell tumors, in non-MAS patients ([@bb0065]).

Gastrointestinal malignancies with hepatobiliary (liver adenomas and choledochal cysts) and pancreatic neoplasms (intraductal papillary mucinous neoplasms - IPMNs) have also been reported in FD ([@bb0155]; [@bb0080]; [@bb0085]). IPMNs occur in up to 50% in patients with MAS ([@bb0165]) whereas pancreatic adenocarcinoma appears to be a rare development in this population, with only 2 reported cases. In these two cases of IPMNs related colloid pancreatic adenocarcinoma in MAS patients, genetic analysis revealed GNAS mutation of the tumor ([@bb0155]; [@bb0085]).

Out of the context of MAS/FD, somatic activating GNAS mutations have also been reported in digestive sporadic tumors, such as hepatocellular adenoma, hepatocellular carcinoma, cholangiocarcinoma and in up to 70% of pancreatic IPMNs ([@bb0140]; [@bb0205]; [@bb0100]; [@bb0075]).

These elements support, on the one hand, the involvement of GNAS mutation in tumorigenesis of hepatobiliary and pancreatic tissue and, on the other hand, the association between MAS and pancreatic neoplasms (IPMNs).

In total, GNAS mutation can affect any tissue and be responsible for malignancy in these.

MAS patients with endocrinopathies should be enrolled in a specific neoplastic screening program. The first step of endocrine malignancies screening is the physical examination (with thyroid, breast, abdomen and testicular palpation) and the biochemistry (with at least, GH, IGF1, prolactin, TSH, T3 and T4). Then, specific imaging exams should be performed, depending on clinical and biological findings, and according to the endocrine organ involved: for instance, pituitary assessment should be completed with an MRI in case of GH excess at biochemistry, and all male with MAS should have baseline testicular ultrasounds ([@bb0095]).

Concerning thyroid, according with recommendations, all patients should have an ultrasound exam, in order to characterize subclinical involvement consistent with MAS ([@bb0095]). Because of the increased risk of thyroid cancer and diagnostic difficulties encountered with ultrasound in patients with MAS (diffusely abnormal thyroid gland making difficult the identification of malignant changes) ([@bb0040]), we believe that, in case of palpable nodule, needle puncture should be advised. Indeed, in this observation, histology revealed thyroid carcinoma whereas ultrasound data was reassuring, with a low risk of malignancy (2--4%) according to TIRADs classification.

Currently, no specific screening is recommended for digestive tumor including IPMNs, but we believe that the most severe cases of MAS and FD (e.g., polyostotic FD, GH excess) should have baseline hepatopancreatobiliary MRI, as suggests by Parvanescu and al ([@bb0155]). Finally, colon cancer screening may be performed in case of excess GH ([@bb0105]).

4. Conclusion {#s0020}
=============

We report the fourth case of thyroid carcinoma GNAS mutated associated with a Mc Cune Albright Syndrome. Outside the context of FD/MAS, a GNAS mutation in thyroid carcinoma has been demonstrated in molecular studies, suggesting that MAS may predispose patients to thyroid carcinomas.

Physicians should keep in mind that the risk of thyroid cancer is higher, but the ultrasound diagnostic is challenging in MAS, guiding to needle puncture of palpable nodules.
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